Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Dirk Huebner

Prospective Study of Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma Patients Who Are Not Suitable for Stem Cell Transplant or Multi-Agent Chemotherapy

British Journal of Haematology

Hematology

2018

English

The Aethera Trial: An Ongoing Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2014

English

Related publications

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

English

Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin

British Journal of Haematology

Hematology

2018

English

Brentuximab Vedotin for Relapsed or Refractory CD30+ Hodgkin Lymphoma: A Multicenter Analysis From Asia

OncoTargets and Therapy

Oncology

Pharmacology

2014

English

PSY5 Comparing Brentuximab Vedotin Overall Survival Data to Standard of Care in Patients With Relapsed/Refractory Hodgkin Lymphoma (HL) Post-Autologous Stem Cell Transplant (ASCT)

English

Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy

2012

English

Brentuximab Vedotin Salvage Followed by Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in High Risk Relapsed Refractory Hodgkin Lymphoma

Hematological Oncology

English

Phase I/Ii Study of Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Patients Treated by Chemotherapy (Ice) in Second Line Before Autologous Transplantation.

Hematological Oncology

English

Real-World Effectiveness of Brentuximab Vedotin Versus Physicians’ Choice Chemotherapy in Patients With Relapsed/Refractory Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the United Kingdom and Germany

Leukemia and Lymphoma

English

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Dirk Huebner

Prospective Study of Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma Patients Who Are Not Suitable for Stem Cell Transplant or Multi-Agent Chemotherapy

The Aethera Trial: An Ongoing Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant

Related publications

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin

Brentuximab Vedotin for Relapsed or Refractory CD30+ Hodgkin Lymphoma: A Multicenter Analysis From Asia

PSY5 Comparing Brentuximab Vedotin Overall Survival Data to Standard of Care in Patients With Relapsed/Refractory Hodgkin Lymphoma (HL) Post-Autologous Stem Cell Transplant (ASCT)

Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma

Brentuximab Vedotin Salvage Followed by Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in High Risk Relapsed Refractory Hodgkin Lymphoma

Phase I/Ii Study of Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Patients Treated by Chemotherapy (Ice) in Second Line Before Autologous Transplantation.

Real-World Effectiveness of Brentuximab Vedotin Versus Physicians’ Choice Chemotherapy in Patients With Relapsed/Refractory Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the United Kingdom and Germany

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)